---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-114457"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:18:28.086074+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# Rhythm Pharmaceuticals terminates setmelanotide license with RareStone for cause over clinical trial breaches

## Summary
- Terminated exclusive license for setmelanotide in Greater China (China, Hong Kong, Macao) effective Oct 28, 2022.
- Termination for cause: RareStone materially breached obligations to fund and perform key clinical studies including EMANATE trial.
- RareStone objects to termination and says formal response is forthcoming; potential dispute or litigation.
- Agreement originally dated Dec 3, 2021 granted RareStone rights to develop and commercialize setmelanotide in Greater China.

## SEC filing metadata
- accession: 0001104659-22-114457
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 1.02, 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000110465922114457/0001104659-22-114457-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000110465922114457/tm2229621d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-114457
- JSON: https://secwatch.observer/filing/0001104659-22-114457.json
- Plain text: https://secwatch.observer/filing/0001104659-22-114457.txt

## Key facts
- Material Agreements
  RHYTHM PHARMACEUTICALS, INC. terminated RareStone License with RareStone Group Ltd. valued at Termination for cause (effective 2022-10-28).
  - Action: termination
  - Agreement: license
  - Counterparty: RareStone Group Ltd.
  - Value: Termination for cause
  - Effective: 2022-10-28
  source text: On October 28, 2022, Rhythm Pharmaceuticals, Inc. (the “Company”) delivered written notice (the “Notice”) to RareStone Group Ltd. (“RareStone”) that the Company has terminated the exclusive license agreement, dated December 3, 2021, by and between the Company and RareStone (the “RareStone License”) for cause.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649904/000110465922114457/0001104659-22-114457-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.